Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Facet Biotech (NASDAQ:FACT.DL)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:FACT.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

fdude71 (< 20)
Submitted February 25, 2010

Very successful fund Baupost owns Facet Biotech (FACT). Facet is a $420 million market capitalization biotech company. A classic value-investor setup that was a spinoff from parent PDL Biopharma (PDLI) in December 2008. Facet contains the former R&D… More

gmxBatteringRam (27.48)
Submitted June 22, 2009

Repost of a blog.Examining Facet BiotechQ: There's been a lot of talk about Facet Biotech (FACT). Why is this company generating discussion?A: Facet is the spinoff of PDL Biopharma (PDLI), which was created to give investors a shot at PDL's drug… More

NASDAQ:FACT.DL Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about FACT.DL.

No one has written a Pitch for FACT.DL stock yet. Tell us why you think FACT.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in FACT.DL.

No players have picked FACT.DL yet. Tell us why you think FACT.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FACT.DL.